Business / Finance

RSS

QIAGEN announces formation of subsidiary in India

QIAGEN today announced the formation of its India subsidiary, QIAGEN India Pvt. Ltd., and the beginning of direct sales in the country. Until now, QIAGEN products have been sold in India through distributor partnerships.

From QIAGEN Manchester Limited 27 Jan 2011

FDA, Simulations Plus sign RCA to develop QSAR toxicity models

Simulations Plus, a leading provider of software for pharmaceutical discovery and development, announced that the U.S. Food and Drug Administration and Simulations Plus have signed a five-year research collaboration agreement to work together to develop Quantitative Structure-Activity Relationship toxicity models for FDA regulatory and research applications.

27 Jan 2011

Alcon fourth quarter sales raise 5.7% to $1.81 billion in 2010

Alcon, Inc. reported that global sales rose 5.7 percent to $1.81 billion for the fourth quarter of 2010. Revenue from acquisitions added 100 basis points to sales growth in the quarter, while foreign currency fluctuations reduced reported sales growth by 20 basis points.

27 Jan 2011

Abbott fourth quarter worldwide sales increase 13.4% to nearly $10 billion

Abbott today announced financial results for the fourth quarter ended Dec. 31, 2010.

27 Jan 2011

Teva announces acquisition of Corporación Infarmasa

Teva Pharmaceutical Industries Ltd. announced today the acquisition of Corporación Infarmasa, a top ten pharmaceutical company in Perú, from The Rohatyn Group and Altra Investments.

27 Jan 2011

It may not be the end for employer-sponsored insurance

A new study finds the effects of health care reform to be minimal on employer-sponsored insurance, despite criticism that changes to how insurance premiums are calculated will force employers to stop offering coverage.

27 Jan 2011

Inviragen completes memorandum of understanding with Duke-NUS

Inviragen, and the Duke-National University of Singapore Graduate Medical School announced today that they have completed a memorandum of understanding to establish a partnership between the two organizations.

27 Jan 2011

Nexstim closes additional equity financing for approximately EUR 11.4 million

Nexstim Oy, a medical device company commercializing noninvasive brain diagnostic and therapy technologies, today announced that it has closed on additional equity financing of approximately EUR 11.4 million.

27 Jan 2011

CyDex stockholders approve merger with Ligand

CyDex Pharmaceuticals, Inc. today announced that its stockholders have voted to approve an Agreement and Plan of Merger between CyDex and Ligand Pharmaceuticals Incorporated and that closing of the transaction has taken place. CyDex will continue its business operations, based in Lenexa, Kansas, as a wholly owned subsidiary of Ligand.

27 Jan 2011

Anapharm Europe, PharmaNet officially terminate joint venture

PharmaNet Development Group, and Anapharm Europe, S.L., both leading providers of drug development services to the pharmaceutical, biotechnology, generic drug and medical device industries, announced that their joint venture for the collaborative provision of bioanalytical services officially ended December 22, 2010.

27 Jan 2011

Teva, APP enter agreement for launch of generic Gemzar

Teva Pharmaceutical Industries Ltd. and APP Pharmaceuticals, Inc. announced today the commercial launch of Gemcitabine HCI for Injection in 200 mg and 1 g single dose vials, the generic version of Gemzar®, in the United States, pursuant to a commercialization, manufacture and supply agreement signed by the two companies.

26 Jan 2011

Lehigh Valley Physician Hospital, Aetna reach agreement on new four-year contract for LVHN

Aetna announced that it has reached agreement on a new four-year contract for Lehigh Valley Health Network with Lehigh Valley Physician Hospital, DBA Valley Preferred.

26 Jan 2011

ICV Partners acquires Stauber Performance Ingredients

ICV Partners, a private investment firm focused on investments in smaller middle market companies, announced today the acquisition of Stauber Performance Ingredients, Inc., a value-added distributor of nutraceutical ingredients to the dietary supplement industry, from J. H. Whitney & Co.

26 Jan 2011

Ligand announces acquisition of CyDex Pharmaceuticals

Ligand Pharmaceuticals Incorporated today announced it has acquired privately held CyDex Pharmaceuticals, for a combination of cash and contingent payments.

26 Jan 2011

Quest Diagnostics fourth quarter revenues decrease 1.3% to $1.8 billion

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, announced that for the fourth quarter ended December 31, 2010, income from continuing operations was $167 million, or $0.97 per diluted share, compared to $182 million, or $0.97 per diluted share, for the fourth quarter of 2009.

From Quest Diagnostics 25 Jan 2011

Nordion and Sterigenics sign five year contract for Cobalt-60 supply

Nordion Inc., a leading provider of products and services to the global health science market, today announced it has signed a five-year contract with Sterigenics International, a global leader in contract sterilization and ionization services, for the supply of Cobalt-60. Under the terms of the agreement, this contract extends until October 31, 2015.

25 Jan 2011

Mylan enters settlement agreement with Pfizer for Caduet Tablets litigation

Mylan Inc. today announced that it has entered into a settlement agreement with Pfizer Inc. resolving litigation related to Caduet® Tablets, 2.5 mg/10, 2.5 mg/20 mg, 2.5 mg/40 mg, 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 5 mg/80 mg, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg and 10 mg/80 mg, known generically as Amlodipine Besylate/Atorvastatin Calcium Tablets.

25 Jan 2011

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Johnson & Johnson today announced sales of $15.6 billion for the fourth quarter of 2010, a decrease of 5.5% as compared to the fourth quarter of 2009. Operational sales declined 5.1% and the negative impact of currency was 0.4%. Domestic sales declined 8.1%, while international sales declined 3.1%, reflecting an operational decline of 2.3% and a negative currency impact of 0.8%.

25 Jan 2011

Corning fourth quarter sales increase 15% to $1.77 billion

Corning Incorporated today announced its results for the fourth quarter of 2010.

25 Jan 2011

Waters fourth quarter sales increase 13% to $484 million

Waters Corporation reported fourth quarter 2010 sales of $484 million, an increase of 13% from sales of $429 million in the fourth quarter of 2009. In the quarter, foreign currency translation was about neutral to sales growth. On a GAAP basis, earnings per diluted share (E.P.S.) for the fourth quarter were $1.36 compared to $1.08 for the fourth quarter of 2009.

25 Jan 2011